March 20, 2014 | Israeli biotech startup Gamida Cell, which develops stem-cell based therapies, is reportedly in advanced acquisition talks at a company value of $600 million. The Times of Israel reports that the company has received a large buy-out offer from an international pharmaceutical company.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments